← Back to patent-cliff list
Tilsotolimod
Tier C — Watch / tradeTilsotolimod
Aceragen Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：TLR9
Indications (approved)：Solid tumour, Melanoma, Hepatitis C
Regional status
US
Phase II
2015-12-01
EU
Phase I
2020-01-22
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Tilsotolimod?
Approved indications include: Solid tumour, Melanoma, Hepatitis C.
When does the Tilsotolimod patent expire?
No public expiry year is available for Tilsotolimod yet; this page updates once verified.
How do I get a quote for Tilsotolimod intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-10